ADCC is an important tumor cell-killing mechanism of action of mAbs including the anti-CCR4 mAb mogamulizumab, which has been approved for CCR4-positive ATL and relapsed/refractory PTCL in Japan. The gene discussed is CCR4; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.